Immunology
Oncolytic viruses move closer to becoming effective cancer therapies
Scientists are identifying key factors that aid in the effectiveness of oncolytic viruses during the treatment of cancers, which could lead to better immunotherapies and inform clinicians which patients might benefit from the treatment. Findings from a June 22 Nature Communications article point to the clinical relevance and underlying mechanisms of a novel anticancer treatment. Read More
What makes immunotherapies successful in one tumor but not in others?
Researchers have developed a new framework to uncover pathophysiological and molecular features that determine the effectiveness of immunotherapies. The research, published in Nature Communications on June 29, provides an opportunity for improving patient care and gaining a deeper understanding of cancer immunotherapy mechanisms. Read More
CAR-NK cells hold promise for solid tumors
A new cancer immunotherapy that leverages the ability of natural killer (NK) cells to discriminate between cancer and normal cells has shown promise in solid tumors. The technology incorporates the cancer-targeting ability of chimeric antigen receptors (CARs), according to data published in iScience on June 25. Read More
How being an effective mentor can advance science
Mentorship in the sciences is about making sure the next generation has the skills needed to be successful and to take science to the next level, explained Michael Howell, PhD, chief scientific officer at DermTech, during a recent conversation with ScienceBoard.net. Read More
FDA issues EUA for monoclonal antibody for treatment of hospitalized COVID-19 patients
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) to Genentech, a member of the Roche Group, for tocilizumab (Actemra) for the treatment of hospitalized adults and pediatric patients. Read More
Advancing from CAR T-cell therapies to modified NK cell therapies
Chimeric antigen receptor (CAR) T-cell therapies have quickly become promising candidates for the treatment of many cancers. However, other immune cell types, such as natural killer (NK) cells, may be effective for some cancers, such as solid tumors, that are traditionally challenging for CAR T therapies. The science behind this concept is worth examining. Read More
Personalized cell therapies offer hope for some of the toughest cancers
Complete with a long-term vision of developing a pipeline of oncology therapies that modulate the functional immune system, Sotio of the Czech Republic is breaking into the world of autologous immuno-oncology therapies. The company's goal is to eventually become a prominent European pharmaceutical firm, according to Radek Špíšek, PhD, CEO and founding scientist of Sotio, who spoke with ScienceBoard.net in a recent interview. Read More
Collaboration targets new treatments for brain diseases
Developing more effective methods to deliver drugs across the blood-brain barrier is the goal of a new collaboration being led by the Wyss Institute for Biologically Inspired Engineering at Harvard University. Read More
NIH initiative tackles structural racism in biomedical research
A new framework to tackle structural racism was introduced by the U.S. National Institutes of Health (NIH) in a commentary published in the journal Cell on June 10. The initiative is an ambitious effort by the NIH to spur widespread, systematic changes across the biomedical research enterprise. Read More
Leveraging past flu pandemics helps build universal flu vaccine
Targeting regions of the influenza virus that do not often change may be an effective strategy for developing next-generation universal flu vaccines, according to new research published in Science Translational Medicine on June 2. Researchers interrogated immune responses from the 2009 H1N1 influenza pandemic to determine which targets to include in new vaccines. Read More
Conferences
BioTech Pharma Summit
September 27-28
Porto Portugal
Infectious Diseases (ID) Week 2021
September 29 - October 3
San Diego, California United States
Imaging Mass Spectrometry Society (IMSS) 3 in 2021
October 3-6
Colorado Springs, Colorado United States
Cell & Gene Meeting on the Mesa
October 10-14
Carlsbad, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter